VERAXA Biotech (NASDAQ: VRXA) announced new in vitro proof-of-concept data supporting its novel BiTAC-ADC technology platform, which is designed to improve precision in cancer treatment through tumor-restricted activation of therapeutic agents. The company reported that BiTAC-ADCs demonstrated the ability to distinguish between breast cancer and healthy cells and achieved dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.
VERAXA said the findings further validate the potential of its BiTAC-ADC platform and complement its BiTAC-TCE technology, providing the company with two differentiated cancer therapy platforms that may be applicable across multiple solid tumor indications. Management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026.
The full press release is available at https://ibn.fm/QiPhH. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
This announcement is significant because it provides early evidence that the BiTAC-ADC platform can address a key challenge in oncology: delivering potent anticancer agents selectively to tumors while sparing healthy tissues. If these results translate to clinical settings, VERAXA's technology could offer a safer and more effective treatment option for patients with solid tumors. The company's dual-platform strategy—combining BiTAC-ADC with BiTAC-TCE—positions it to target multiple cancer types through different mechanisms of action, potentially broadening its therapeutic reach.
Forward-looking statements in this press release involve risks and uncertainties, including those detailed in VERAXA's SEC filings. Investors should not place undue reliance on these statements. The company undertakes no duty to update this information unless required by law.
